Boost for cheaper drugs: SC rejects Novartis patent on Glivec

In a landmark judgement, India’s Supreme Court today rejected a patent plea by Swiss drugmaker Novartis AG for cancer drug Glivec, boosting the case for cheaper drugs for life-threatening diseases. The decision in the seven-year legal battle was keenly awaited by the two most interested parties— big pharma companies and health aid groups — with both sides saying the outcome will set a precedent with far-reaching consequences for the future availability of the drugs.

Read Full Story>>